文献速递脊柱脊髓外科

前瞻性随机多中心研究并随访2年比较减压联与不联层间稳定术的性能

Prospective, randomized, multicenter study with 2-year follow-up to compare the performance of decompression with and without interlaminar stabilization.
PubMed 文献 · J Neurosurg Spine · 2018-01-26

230例中度至重度腰椎管狭窄症患者随机分配至单纯减压(DA)或减压联合层间稳定术(D+ILS),在德国7个中心治疗并随访2年。两组患者报告结局无显著差异,但D+ILS组复合临床成功率更优(p=0.017),DA组二次干预风险为D+ILS组的1.75倍(p=0.055),DA组腰椎注射更多(14.8% vs 4.5%,p=0.0065)。

要点

  • D+ILS组复合临床成功率优于DA组(p=0.017)。
  • DA组二次干预风险为D+ILS组的1.75倍(p=0.055)。
  • DA组腰椎注射比例高于D+ILS组(14.8% vs 4.5%,p=0.0065)。

核心结论

  • 单独看患者报告结局(如ODI、VAS、ZCQ)两组间无显著差异。
  • 复合临床成功(生存、ODI成功、无神经功能恶化或器械/手术相关严重不良事件)在D+ILS组具统计学优势。
  • 显微手术D+ILS增加步行距离、减少代偿性疼痛管理并维持影像学椎间孔高度。

研究设计与样本

  • 前瞻性、随机、多中心研究,随访2年,在德国7个中心进行。
  • 230例患者按1:1随机分配至单纯减压(DA)组或减压联合层间稳定术(D+ILS)组。
  • 患者为L3至L5单或双相邻节段中度至重度腰椎管狭窄症。

主要发现

  • 2年随访率为91%。
  • 24个月时患者报告结局无显著差异(p>0.05)。
  • 复合临床成功率D+ILS组优于DA组(p=0.017)。
  • DA组二次干预风险为D+ILS组的1.75倍(p=0.055)。
  • DA组腰椎注射较D+ILS组多228%(D+ILS组4.5% vs DA组14.8%,p=0.0065)。

关键数值与推荐

  • 复合临床成功定义为联合以下4项结局:ODI成功、无二次手术或腰椎注射、神经功能状态稳定、无器械或手术相关严重不良事件。
  • DA组术后各时间点麻醉药品使用率数值上更高(24个月时D+ILS组16.7% vs DA组23%)。
  • 步行距离测试结果较基线有统计学显著差异,D+ILS组改善程度为DA组的2倍以上;D+ILS组较基线改善超过5倍,而DA组仅为基线的2倍。
  • D+ILS组椎间孔高度和椎间盘高度基本维持,DA组术后24个月显著下降(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Surgical decompression is extremely effective in relieving pain and symptoms due to lumbar spinal stenosis (LSS). Decompression with interlaminar stabilization (D+ILS) is as effective as decompression with posterolateral fusion for stenosis, as shown in a major US FDA pivotal trial. This study reports a multicenter, randomized controlled trial in which D+ILS was compared with decompression alone (DA) for treatment of moderate to severe LSS. METHODS Under approved institutional ethics review, 230 patients (1:1 ratio) randomized to either DA or D+ILS (coflex, Paradigm Spine) were treated at 7 sites in Germany. Patients had moderate to severe LSS at 1 or 2 adjacent segments from L-3 to L-5. Outcomes were evaluated up to 2 years postoperatively, including Oswestry Disability Index (ODI) scores, the presence of secondary surgery or lumbar injections, neurological status, and the presence of device- or procedure-related severe adverse events. The composite clinical success (CCS) was defined as combining all 4 of these outcomes, a success definition validated in a US FDA pivotal trial. Additional secondary end points included visual analog scale (VAS) scores, Zürich Claudication Questionnaire (ZCQ) scores, narcotic usage, walking tolerance, and radiographs. RESULTS The overall follow-up rate was 91% at 2 years. There were no significant differences in patient-reported outcomes at 24 months (p > 0.05). The CCS was superior for the D+ILS arm (p = 0.017). The risk of secondary intervention was 1.75 times higher among patients in the DA group than among those in the D+ILS group (p = 0.055). The DA arm had 228% more lumbar injections (4.5% for D+ILS vs 14.8% for DA; p = 0.0065) than the D+ILS one. Patients who underwent DA had a numerically higher rate of narcotic use at every time point postsurgically (16.7% for D+ILS vs 23% for DA at 24 months). Walking Distance Test results were statistically significantly different from baseline; the D+ILS group had > 2 times the improvement of the DA. The patients who underwent D+ILS had > 5 times the improvement from baseline compared with only 2 times the improvement from baseline for the DA group. Foraminal height and disc height were largely maintained in patients who underwent D+ILS, whereas patients treated with DA showed a significant decrease at 24 months postoperatively (p < 0.001). CONCLUSIONS This study showed no significant difference in the individual patient-reported outcomes (e.g., ODI, VAS, ZCQ) between the treatments when viewed in isolation. The CCS (survivorship, ODI success, absence of neurological deterioration or device- or procedure-related severe adverse events) is statistically superior for ILS. Microsurgical D+ILS increases walking distance, decreases compensatory pain management, and maintains radiographic foraminal height, extending the durability and sustainability of a decompression procedure. Clinical trial registration no.: NCT01316211 (clinicaltrials.gov).

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Schmidt S, Franke J, Rauschmann M, et al. Prospective, randomized, multicenter study with 2-year follow-up to compare the performance of decompression with and without interlaminar stabilization. J Neurosurg Spine. 2018. PMID: 29372860. doi:10.3171/2017.11.SPINE17643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。